{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:40:39Z","timestamp":1777894839086,"version":"3.51.4"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T00:00:00Z","timestamp":1663545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"grant from the Ministry of Science and Technology of China","award":["2016YFC0105207"],"award-info":[{"award-number":["2016YFC0105207"]}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"crossref","award":["2021-I2M-C&T-B-002"],"award-info":[{"award-number":["2021-I2M-C&T-B-002"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"crossref","award":["2017-I2M-1-001"],"award-info":[{"award-number":["2017-I2M-1-001"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"DOI":"10.1007\/s40618-022-01908-1","type":"journal-article","created":{"date-parts":[[2022,9,19]],"date-time":"2022-09-19T14:22:08Z","timestamp":1663597328000},"page":"477-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Favorable outcome in advanced pheochromocytoma and paraganglioma after hypofractionated intensity modulated radiotherapy"],"prefix":"10.1007","volume":"46","author":[{"given":"Z.","family":"Gu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Tong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4903-9489","authenticated-orcid":false,"given":"X.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,19]]},"reference":[{"issue":"9486","key":"1908_CR1","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366(9486):665\u2013675. https:\/\/doi.org\/10.1016\/S0140-6736(05)67139-5","journal-title":"Lancet"},{"issue":"6","key":"1908_CR2","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1210\/jc.2014-1498","volume":"99","author":"JW Lenders","year":"2014","unstructured":"Lenders JW, Duh QY, Eisenhofer G et al (2014) Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 99(6):1915\u20131942. https:\/\/doi.org\/10.1210\/jc.2014-1498","journal-title":"J Clin Endocrinol Metab"},{"key":"1908_CR3","unstructured":"Kl\u00f6ppel G, Hruban R. 2017 WHO classification of tumours of endocrine organs: Lyon: International Agency for Research on Cancer 2017"},{"issue":"5","key":"1908_CR4","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/cen.13434","volume":"87","author":"O Hamidi","year":"2017","unstructured":"Hamidi O, Young WF Jr, Gruber L et al (2017) Outcomes of patients with metastatic phaeochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 87(5):440\u2013450. https:\/\/doi.org\/10.1111\/cen.13434","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"1908_CR5","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1007\/s40618-021-01629-x","volume":"45","author":"G De Filpo","year":"2022","unstructured":"De Filpo G, Cantini G, Rastrelli G et al (2022) Management and outcome of metastatic pheochromocytomas\/paragangliomas: a monocentric experience. J Endocrinol Invest 45(1):149\u2013157. https:\/\/doi.org\/10.1007\/s40618-021-01629-x","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"1908_CR6","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1002\/ijc.28913","volume":"135","author":"J Hadoux","year":"2014","unstructured":"Hadoux J, Favier J, Scoazec JY et al (2014) SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. Int J Cancer 135(11):2711\u20132720. https:\/\/doi.org\/10.1002\/ijc.28913","journal-title":"Int J Cancer"},{"issue":"12","key":"1908_CR7","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1038\/s41416-019-0474-x","volume":"120","author":"GM O'Kane","year":"2019","unstructured":"O\u2019Kane GM, Ezzat S, Joshua AM et al (2019) A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial. Br J Cancer 120(12):1113\u20131119. https:\/\/doi.org\/10.1038\/s41416-019-0474-x","journal-title":"Br J Cancer"},{"issue":"1","key":"1908_CR8","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/jcm10010088[","volume":"10","author":"G Fanciulli","year":"2020","unstructured":"Fanciulli G, Di Molfetta S, Dotto A et al (2020) Emerging therapies in pheochromocytoma and paraganglioma: immune checkpoint inhibitors in the starting blocks. J Clin Med 10(1):88. https:\/\/doi.org\/10.3390\/jcm10010088[","journal-title":"J Clin Med"},{"issue":"6","key":"1908_CR9","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1111\/cen.14106[","volume":"91","author":"S Satapathy","year":"2019","unstructured":"Satapathy S, Mittal BR, Bhansali A (2019) Peptide receptor radionuclide therapy in the management of advanced pheochromocytoma and paraganglioma: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 91(6):718\u2013727. https:\/\/doi.org\/10.1111\/cen.14106[","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"15","key":"1908_CR10","doi-asserted-by":"publisher","first-page":"TPS4159","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS4159","volume":"37","author":"F Lin","year":"2019","unstructured":"Lin F, Rivero JD, Carrasquillo JA, Jha A, Pacak K (2019) Phase 2 trial of Lu-177-DOTATATE in inoperable pheochromocytoma\/paraganglioma. J Clin Oncol 37(15):TPS4159\u2013TPS4259","journal-title":"J Clin Oncol"},{"issue":"1","key":"1908_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.adro.2017.11.002","volume":"3","author":"W Breen","year":"2018","unstructured":"Breen W, Bancos I, Young WF Jr et al (2018) External beam radiation therapy for advanced\/unresectable malignant paraganglioma and pheochromocytoma. Adv Radiat Oncol 3(1):25\u201329. https:\/\/doi.org\/10.1016\/j.adro.2017.11.002","journal-title":"Adv Radiat Oncol"},{"key":"1908_CR12","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fonc.2014.00166","volume":"4","author":"J Vogel","year":"2014","unstructured":"Vogel J, Atanacio AS, Prodanov T et al (2014) External beam radiation therapy in treatment of malignant pheochromocytoma and paraganglioma. Front Oncol 4:166. https:\/\/doi.org\/10.3389\/fonc.2014.00166","journal-title":"Front Oncol"},{"issue":"5","key":"1908_CR13","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1055\/s-0032-1308992","volume":"44","author":"L Fishbein","year":"2012","unstructured":"Fishbein L, Bonner L, Torigian DA et al (2012) External beam radiation therapy (EBRT) for patients with malignant pheochromocytoma and non-head and -neck paraganglioma: combination with 131I-MIBG. Horm Metab Res 44(5):405\u2013410. https:\/\/doi.org\/10.1055\/s-0032-1308992","journal-title":"Horm Metab Res"},{"issue":"1","key":"1908_CR14","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40618-020-01344-z","volume":"44","author":"G De Filpo","year":"2021","unstructured":"De Filpo G, Maggi M, Mannelli M, Canu L (2021) Management and outcome of metastatic pheochromocytomas\/paragangliomas: an overview. J Endocrinol Invest 44(1):15\u201325. https:\/\/doi.org\/10.1007\/s40618-020-01344-z","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1908_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45(2):228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"issue":"5","key":"1908_CR16","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/0360-3016(95)00060-C","volume":"31","author":"JD Cox","year":"1995","unstructured":"Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31(5):1341\u20131346. https:\/\/doi.org\/10.1016\/0360-3016(95)00060-C","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1908_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s40618-021-01729-8","volume":"45","author":"S Batchu","year":"2022","unstructured":"Batchu S, Hakim A, Henry OS et al (2022) Transcriptome-guided resolution of tumor microenvironment interactions in pheochromocytoma and paraganglioma subtypes. J Endocrinol Invest 45(5):989\u2013998. https:\/\/doi.org\/10.1007\/s40618-021-01729-8","journal-title":"J Endocrinol Invest"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-022-01908-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-022-01908-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,17]],"date-time":"2023-02-17T10:05:16Z","timestamp":1676628316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-022-01908-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,19]]},"references-count":17,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["1908"],"URL":"https:\/\/doi.org\/10.1007\/s40618-022-01908-1","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,19]]},"assertion":[{"value":"13 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics requirements"}},{"value":"All procedures were approved by Peking Union Medical College Hospital Ethics Committee (Approval No. S-K 1886), and the document (scanned version in Chinese) is uploaded to the attachment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statement of human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}